Ozonized low density lipoprotein (ozLDL) inhibits NF-κB and IRAK-1-associated signaling

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 1, 2007, Pages 226-232

  Cappello, Christian ^a   Saugel, Bernd ^a   Huth, Karin C ^b   Zwergal, Andreas ^a   Krautkrämer, Martina ^a   Furman, Christophe ^c   Rouis, Mustapha ^c   Wieser, Bianca ^a   Schneider, Heike W ^a   Neumeier, Dieter ^a   Brand, Korbinian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Atherosclerosis; IRAK 1; NF B; Ozone; Ozonized LDL

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN; OZONE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; OZONATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; ATHEROSCLEROSIS; CELL LINE; CYTOLOGY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

APOPTOSIS; ATHEROSCLEROSIS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; LIPOPOLYSACCHARIDES; LIPOPROTEINS, LDL; MONOCYTES; NF-KAPPA B; OZONE; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 33847654637     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000250615.27795.85     Document Type: Article

References (30)

1. Wentworth P Jr, Nieva J, Takeuchi C, Galve R, Wentworth AD, Dilley RB, DeLaria GA, Saven A, Babior BM, Janda KD, Eschenmoser A, Lerner RA. Evidence for ozone formation in human atherosclerotic arteries. Science. 2003;302:1053-1056.
2. Wentworth P Jr, McDunn JE, Wentworth AD, Takeuchi C, Nieva J, Jones T, Bautista C, Ruedi JM, Gutierrez A, Janda KD, Babior BM, Eschenmoser A, Lerner RA. Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science. 2002;298:2195-2199.
3. Lerner RA, Eschenmoser A. Ozone in biology. Proc Natl Acad Sci U S A. 2003;100:3013-3015.
4. Zhu X, Wentworth P Jr, Wentworth AD, Eschenmoser A, Lerner RA, Wilson IA. Probing the antibody-catalyzed water-oxidation pathway at atomic resolution. Proc Natl Acad Sci U S A. 2004;101:2247-2252.
5. Glass CK, Witztum JL.Atherosclerosis. The road ahead. Cell. 2001;104:503-516.
6. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
7. Yla-Herttuala S. Is oxidized low-density lipoprotein present in vivo? Curr Opin Lipidol. 1998;9:337-344.
8. Ghosh S, Karin M Missing pieces in the NF-kappaB puzzle. Cell. 2002;109 Suppl:S81-96.
9. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001;107:3-6.
10. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-1722.
11. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471-478.
12. Ares MP, Kallin B, Eriksson P, Nilsson J. Oxidized LDL induces transcription factor activator protein-1 but inhibits activation of nuclear factor-kappa B in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1995;15:1584-1590.
13. Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, Kaltschmidt C, Neumann FJ, Mackman N, Baeuerle PA, Walli AK, Neumeier D. Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol. 1997;17:1901-1909.
14. Tobias P, Curtiss LK. Thematic review series: The immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. J Lipid Res. 2005;46:404-411.
15. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;91:281-291.
16. Janssens S, Beyaert R. Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members. Mol Cell. 2003;11:293-302.
17. Quirling M, Page S, Jilg N, Plenagl K, Peus D, Grubmüller C, Weingärtner M, Fischer C, Neumeier D, Brand K. Detection of IKKbeta-IKKgamma subcomplexes in monocytic cells and characterization of associated signaling. J Biol Chem. 2004;279:37452-37460.
18. Page S, Fischer C, Baumgärtner B, Haas M, Kreusel U, Loidl G, Hayn M, Ziegler-Heitbrock HW, Neumeier D, Brand K. 4-Hydroxynonenal prevents NF-kappaB activation and tumor necrosis factor expression by inhibiting IkappaB phosphorylation and subsequent proteolysis. J Biol Chem. 1999;274:11611-11618.
19. Gumulka J, Smith LL. Ozonation of cholesterol. J Am Chem Soc. 1983;105:1972-1979.
20. Marx J. Medicine. Ozone may be secret ingredient in plaques' inflammatory stew. Science. 2003;302:965.
21. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem. 1995;270:17050-17055.
22. Rajavashisth TB, Yamada H, Mishra NK. Transcriptional activation of the macrophage-colony stimulating factor gene by minimally modified LDL. Involvement of nuclear factor-kappa B. Arterioscler Thromb Vasc Biol. 1995;15:1591-1598.
23. Ohlsson BG, Englund MC, Karlsson AL, Knutsen E, Erixon C, Skribeck H, Liu Y, Bondjers G, Wiklund O. Oxidized low density lipoprotein inhibits lipopolysaccharide-induced binding of nuclear factor-kappaB to DNA and the subsequent expression of tumor necrosis factor-alpha and interleukin-1beta in macrophages. J Clin Invest. 1996;98:78-89.
24. Schackelford RE, Misra UK, Florine-Casteel K, Thai SF, Pizzo SV, Adams DO. Oxidized low density lipoprotein suppresses activation of NF kappa B in macrophages via a pertussis toxin-sensitive signaling mechanism. J Biol Chem. 1995;270:3475-3478.
25. Hamilton TA, Major JA, Armstrong D, Tebo JM. Oxidized LDL modulates activation of NFkappaB in mononuclear phagocytes by altering the degradation of IkappaBs. J Leukoc Biol. 1998;64:667-674.
26. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634-1635.
27. Mackman N. How do oxidized phospholipids inhibit LPS signaling? Arterioscler Thromb Vasc Biol. 2003;23:1133-1136.
28. Bochkov VN, Kadl A, Huber J, Gruber F, Binder BR, Leitinger N. Protective role of phospholipid oxidation products in endotoxin-induced tissue damage. Nature. 2002;419:77-81.
29. Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med. 2005;353:9-11.
30. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol. 2005;25:1776-1785.